473 related articles for article (PubMed ID: 32224379)
1. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview.
Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
Eur J Med Chem; 2020 May; 194():112260. PubMed ID: 32224379
[TBL] [Abstract][Full Text] [Related]
2. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
[TBL] [Abstract][Full Text] [Related]
3. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.
Rashid ZA; Bardaweel SK
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569509
[TBL] [Abstract][Full Text] [Related]
4. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.
Fields GB
Front Immunol; 2019; 10():1278. PubMed ID: 31214203
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
Das S; Amin SA; Jha T
Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.
Chen C; Yang X; Fang H; Hou X
Eur J Med Chem; 2019 Nov; 181():111563. PubMed ID: 31415980
[TBL] [Abstract][Full Text] [Related]
9. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
[TBL] [Abstract][Full Text] [Related]
10. Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.
Kim IS; Yang WS; Kim CH
Curr Med Chem; 2023; 30(18):2075-2112. PubMed ID: 36017851
[TBL] [Abstract][Full Text] [Related]
11. Outline of gelatinase inhibitors as anti-cancer agents: A patent mini-review for 2010-present.
Baidya SK; Amin SA; Jha T
Eur J Med Chem; 2021 Mar; 213():113044. PubMed ID: 33279289
[TBL] [Abstract][Full Text] [Related]
12. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
Senn N; Ott M; Lanz J; Riedl R
J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of 4-phenoxybenzenesulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Mao J; Zhang H; Wang X; Gao J; Tang J; Zhang J
Biosci Trends; 2020 Jul; 14(3):192-199. PubMed ID: 32389938
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS; Lin CW; Su SC; Yang SF
Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
[TBL] [Abstract][Full Text] [Related]
16. Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation.
Albelwi FF; Teleb M; Abu-Serie MM; Moaty MNAA; Alsubaie MS; Zakaria MA; El Kilany Y; Aouad MR; Hagar M; Rezki N
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638665
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Evaluation of New Oxadiazole, Thiadiazole, and Triazole Derivatives as Potential Anticancer Agents Targeting MMP-9.
Özdemir A; Sever B; Altıntop MD; Temel HE; Atlı Ö; Baysal M; Demirci F
Molecules; 2017 Jul; 22(7):. PubMed ID: 28677624
[TBL] [Abstract][Full Text] [Related]
18. Status of research on matrix metalloproteinases (MMPs) in India.
Bulbule A; Saraswati S; Kundu GC
Expert Opin Ther Targets; 2011 Jun; 15(6):671-5. PubMed ID: 21476880
[TBL] [Abstract][Full Text] [Related]
19. A fragment-based structural analysis of MMP-2 inhibitors in search of meaningful structural fragments.
Banerjee S; Amin SA; Jha T
Comput Biol Med; 2022 May; 144():105360. PubMed ID: 35278773
[TBL] [Abstract][Full Text] [Related]
20. Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023).
Almutairi S; Kalloush HM; Manoon NA; Bardaweel SK
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]